Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Relapsed or Refractory DLBCL | US/EU | 2023
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Unmet Need – Detailed, Expanded Analysis: Relapsed or Refractory DLBCL (US/EU)
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2023
Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Treatment Sequencing | US | 2023
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2022
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | China In-Depth | China | 2022
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Middle East & Africa
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Asia-Pacific
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Americas
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
